PubMed Health⌕ Search

Biomedical subjects

Angela Baker

Publications and source records attributed to Angela Baker.

2 recordsLinked to original sources

Shiftwork experience and the value of time.

Dissatisfaction with shiftwork has been shown to increase with age and work experience. The objective was to determine if differences in preferred paid work time existed between shiftworkers with different lengths of shiftwork experience and age-matched non-shiftworkers (controls). A questionnaire was used to determine how controls and shiftworkers with different shiftwork experience perceived the value of preferred work time across the week. Participants were required to value each hour across the days of the week on a scale from 0 (least preference) to 10 (highest preference). Data were analysed across groups to produce mean and standard deviation matrices. Unpaired t-tests determined significant differences between groups. This study found that preferred hours-of-work change with years of shiftwork experience. For shiftworkers in their first 5 years and those in their 30th-year-plus of shiftwork, night work was a low priority. Shiftworkers with 17 - 30 years experience indicated a preference for work any time across the week. Overall, shiftworkers extended their preferred work hours to include the evenings and weekend. Controls adhered more strongly to current societal norms. The results suggest that a person initially undertaking shiftwork may well be one with a less restrictive perception of time and its use, however, this perception may alter over time.

Adult↗

Uteroglobin: a potential novel tumor suppressor and molecular therapeutic for prostate cancer.

Currently, there are very few diagnostic or therapeutic strategies targeted at controlling tumor growth and progression towards metastasis. Uteroglobin (UG) is a naturally occurring, small, stable, secretory protein that is normally expressed by most cells of epithelial origin but is known to be lost during the progression of prostate, lung, and uterine cancers to invasive malignancy. Uteroglobin -/- knockout mice appear to be extremely cancer prone. Both pharmacological and transgenic reconstitution of recombinant human UG (rhUG) to prostate, lung, and endometrial tumor cell lines markedly inhibits their invasiveness and antagonizes the neoplastic phenotype. In preliminary studies, rhUG inhibited angiogenesis in the ex vivo rat aorta model and showed antitumor activity against human prostate tumor cells (PC-3) in the chick chorioallantoic membrane assay, reducing both tumor volume and vascularity. A recent in vivo pilot study showed that twice daily dosing with rhUG resulted in a statistically significant increase in survival without evidence of toxicity in severe combined immunodeficient mice challenged with a PC-3 cell metastasizing tumor. Thus, rhUG may slow the progression of cancer by inhibiting both tumor cell invasiveness and tumor angiogenesis. It therefore holds the potential to serve as a new weapon in the arsenal of cytostatic, antimetastatic, adjuvant treatment for cancer. In this paper, we will briefly discuss the therapeutic potential of uteroglobin-based strategies for managing prostate cancer.

Animals↗